Germany's IQWiG backs Bristol-Myers' Opdivo in melanoma; Pfizer ALL med inotuzumab gets 'breakthrough' status;

> German cost-effectiveness gatekeepers decided that Bristol-Myers Squibb's ($BMY) immuno-oncology treatment Opdivo offers an "added benefit" over previous treatments, particularly in men. Report

> Pfizer ($PFE) scored the FDA's breakthrough therapy designation on inotuzumab, its experimental drug for acute lymphoblastic leukemia, the third of Pfizer's cancer candidates to win that status. Report

> Allergan ($AGN) expanded its portfolio of dry-eye remedies with the launch of the over-the-counter Refresh Optive Gel Drops. Release

> LEO Pharma won FDA approval for Enstilar, its topical foam treatment for psoriasis vulgaris in patients 18 and older. Report

And Finally... Novartis' ($NVS) new affordable-drugs scheme for emerging markets launched in Kenya. Release

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.